NMS-P937 is primarily investigated for its potential in cancer therapy, particularly as a polo-like kinase 1 (PLK1) inhibitor. PLK1 plays a critical role in cell division, making it a promising target for inhibiting the proliferation of cancer cells. By blocking PLK1 activity, NMS-P937 disrupts the mitotic process, leading to cell cycle arrest and apoptosis in tumor cells. This mechanism is especially relevant in targeting cancers with high PLK1 expression, such as certain types of breast, lung, and colorectal cancers. Preclinical studies have shown its efficacy in reducing tumor growth, making it a candidate for further development in oncology research. Its application is currently focused on understanding its therapeutic potential and optimizing its use in combination with other anticancer agents.